Pfizer executives said most patients experienced few or mild side effects, with gastrointestinal events largely limited to early doses and clustered close to when patients received the shot.
Pfizer executives said most patients experienced few or mild side effects, with gastrointestinal events largely limited to early doses and clustered close to when patients received the shot.